This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Teneligliptin
- DrugBank Accession Number
- DB11950
- Background
Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Teneligliptin (DB11950)
- Weight
- Average: 426.578
Monoisotopic: 426.220180302 - Chemical Formula
- C22H30N6OS
- Synonyms
- Teneligliptin
- External IDs
- MP-513
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Teneligliptin. Acebutolol The therapeutic efficacy of Teneligliptin can be increased when used in combination with Acebutolol. Acetazolamide The therapeutic efficacy of Teneligliptin can be increased when used in combination with Acetazolamide. Acetohexamide Teneligliptin may increase the hypoglycemic activities of Acetohexamide. Acetyl sulfisoxazole The therapeutic efficacy of Teneligliptin can be increased when used in combination with Acetyl sulfisoxazole. Acetylsalicylic acid The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Teneligliptin. Albiglutide The risk or severity of hypoglycemia can be increased when Albiglutide is combined with Teneligliptin. Alclometasone The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Teneligliptin. Alogliptin The risk or severity of angioedema can be increased when Alogliptin is combined with Teneligliptin. Alteplase The risk or severity of angioedema can be increased when Alteplase is combined with Teneligliptin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- A10BH08 — Teneligliptin
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- N-arylpiperazines / Phenylpyrazoles / Dialkylarylamines / Pyrrolidinecarboxamides / N-alkylpiperazines / Benzene and substituted derivatives / Heteroaromatic compounds / Tertiary carboxylic acid amides / Thiazolidines / Trialkylamines show 7 more
- Substituents
- 1,4-diazinane / Alpha-amino acid amide / Amine / Aromatic heteromonocyclic compound / Azacycle / Azole / Benzenoid / Carbonyl group / Carboxamide group / Dialkylarylamine show 26 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 28ZHI4CF9C
- CAS number
- 760937-92-6
- InChI Key
- WGRQANOPCQRCME-PMACEKPBSA-N
- InChI
- InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
- IUPAC Name
- 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-4-[(3S,5S)-5-(1,3-thiazolidine-3-carbonyl)pyrrolidin-3-yl]piperazine
- SMILES
- [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1
References
- General References
- FDA Thailand Product Information: Tenelia (teneligliptin) oral tablets [Link]
- External Links
- PubChem Compound
- 11949652
- PubChem Substance
- 347828276
- ChemSpider
- 10123963
- BindingDB
- 50391565
- ChEBI
- 136042
- ChEMBL
- CHEMBL2147777
- ZINC
- ZINC000036520254
- PDBe Ligand
- M51
- Wikipedia
- Teneligliptin
- PDB Entries
- 3vjk
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Type 2 Diabetes Mellitus 4 4 Recruiting Treatment Type 2 Diabetes Mellitus 1 4 Unknown Status Treatment Type 2 Diabetes Mellitus 1 3 Completed Treatment Type 2 Diabetes Mellitus 13 3 Recruiting Treatment Type 2 Diabetes Mellitus 2 2 Completed Treatment Type 2 Diabetes Mellitus 2 1 Completed Other Diabetes Mellitus 1 1 Completed Other Healthy Subjects (HS) 2 1 Completed Treatment Diabetes Mellitus 1 1 Completed Treatment Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, coated Oral 20 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.4 mg/mL ALOGPS logP 1.69 ALOGPS logP 1.42 Chemaxon logS -2.5 ALOGPS pKa (Strongest Basic) 9.38 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 56.64 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 121.78 m3·mol-1 Chemaxon Polarizability 46.91 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:03 / Updated at February 21, 2021 18:53